DNA & Clones

DNA was prepared from cell line WM3792. WM3792 is a metastatic human melanoma cell line that displays a dendritic morphology. This cell line contains V600K (Val600Lys) mutation at codon 600 in the BRAF gene. This mutation occurs within the activation segment of the kinase domain and causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses a novel mutation––the deletion of codon 601, and contains a PTEN loss of function including homozygous deletion. WM3792 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM3792. WM3792 is a metastatic human melanoma cell line that displays a dendritic morphology. This cell line contains V600K (Val600Lys) mutation at codon 600 in the BRAF gene. This mutation occurs within the activation segment of the kinase domain and causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses a novel mutation––the deletion of codon 601, and contains a PTEN loss of function including homozygous deletion. WM3792 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM3854. WM3854 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line was established from a heavily pigmented metastatic site (right upper flank of back) in a 64-year-old male with superficial and deep inguinal nodes forming a 3.0 cm mass. This cell line contains a Q61L mutation at position 61 in the N-RAS gene which causes increased signaling via the extracellular signal-regulated MAPK/ERK kinase pathways to enhance proliferation. This cell line is known to be wild type for BRAF, c-KIT and CDK4. WM3854 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM3854. WM3854 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line was established from a heavily pigmented metastatic site (right upper flank of back) in a 64-year-old male with superficial and deep inguinal nodes forming a 3.0 cm mass. This cell line contains a Q61L mutation at position 61 in the N-RAS gene which causes increased signaling via the extracellular signal-regulated MAPK/ERK kinase pathways to enhance proliferation. This cell line is known to be wild type for BRAF, c-KIT and CDK4. WM3854 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM3854. WM3854 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line was established from a heavily pigmented metastatic site (right upper flank of back) in a 64-year-old male with superficial and deep inguinal nodes forming a 3.0 cm mass. This cell line contains a Q61L mutation at position 61 in the N-RAS gene which causes increased signaling via the extracellular signal-regulated MAPK/ERK kinase pathways to enhance proliferation. This cell line is known to be wild type for BRAF, c-KIT and CDK4. WM3854 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM39. WM39 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses R24C mutation at position 24 in the CDK4 gene. The R24C mutation results in an amino acid substitution at codon 24 in CDK4, from an arginine (R) to cysteine (C). This mutation abolishes the ability of CDK4 to bind to p16(INK4a). WM39 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM39. WM39 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses R24C mutation at position 24 in the CDK4 gene. The R24C mutation results in an amino acid substitution at codon 24 in CDK4, from an arginine (R) to cysteine (C). This mutation abolishes the ability of CDK4 to bind to p16(INK4a). WM39 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM39. WM39 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses R24C mutation at position 24 in the CDK4 gene. The R24C mutation results in an amino acid substitution at codon 24 in CDK4, from an arginine (R) to cysteine (C). This mutation abolishes the ability of CDK4 to bind to p16(INK4a). WM39 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM3912. WM3912 is a metastatic human melanoma cell line established from a neck metastatic site of a patient. This cell line thaws poorly and contains lots of spontaneous senescent cells. This cell line features the N581Y mutation at codon 581 in the BRAF gene. The N581Y mutation results in an amino acid substitution at position 581 in the BRAF, from an asparagine (N) to a tyrosine (Y). This cell line also expresses L213F mutation in CDK4 gene which results in an amino acid substitution at codon 213 in the CDK4 from leucine (L) to phenylalanine (F). WM3912 cells produce xenograft tumors when injected into immunocompromised mice.